Mayne Pharma has acquired the rights to the fentanyl transdermal delivery system (TDS), from Par Pharmaceutical Inc. The product was developed by Corium, a specialty pharma company focused on the development and manufacture of transdermal and transmucosal delivery systems.  Fentanyl TDS is a generic equivalent to Duragesic, indicated for severe pain management in opioid-tolerant patients requiring daily treatment. Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium, ...